Aspergillus Fumigatus Asthma Model
Aspergillus Fumigatus Asthma Model - Related Videos
08:05
Murine Model of Allergen Induced Asthma
0 Views •
Cited by 51 •
2012
Experimental mouse models of allergic asthma offer new possibilities for studying disease pathogenesis and developing new therapeutics. These models are well suited to measuring factors governing the allergic immune response, airway inflammation, and pulmonary pathophysiology.
09:43
Measuring Phagocytosis of Aspergillus fumigatus Conidia by Human Leukocytes using Flow Cytometry
0 Views •
Cited by 2 •
2019
This protocol provides a fast and reliable method to quantitatively measure phagocytosis of Aspergillus fumigatus conidia by human primary phagocytes using flow cytometry and to discriminate phagocytosis of conidia from mere adhesion to leukocytes.
12:29
Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
0 Views •
Cited by 10 •
2017
Here, we describe a protocol to assess antifungal activity of primary human immune cells in real-time using fluorescent Aspergillus reporter conidia in conjunction with live-cell video microscopy and flow cytometry. Generated data provide insight into host cell-Aspergillus interactions such as fungicidal activity, phagocytosis, cell migration and inhibition of fungal growth.
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
0 Views •
Cited by 4 •
2010
Bronchial thermoplasty is a non-drug procedure for severe persistent asthma that delivers thermal energy to the airway wall in a precisely controlled manner to reduce excessive airway smooth muscle. Reducing airway smooth muscle decreases the ability of the airways to constrict, thereby reducing the frequency of asthma attacks.
10:51
Customization of Aspergillus niger Morphology Through Addition of Talc Micro Particles
0 Views •
Cited by 32 •
2012
A method to precisely generate and to comprehensively characterize morphology of filamentous fungus Aspergillus niger is described, which allows the mathematical correlation of morphological appearance and productivity.
FAQs
Exposure to Aspergillus fumigatus antigens activates type 2 inflammation in the airways. This response is associated with immunoglobulin E production, eosinophil recruitment, increased mucus secretion, and airway hyperresponsiveness. Measuring these linked outcomes allows investigators to connect recognition of fungal material with immune activation and changes in airway function rather than examining inflammation as an isolated event.
The model is used to examine interactions among fungal antigens, the airway epithelium, and adaptive immunity. Fungal material provides the relevant environmental stimulus, while airway tissues and immune responses contribute to the resulting disease features. Studying these components together helps researchers identify how local airway responses connect with antigen-specific immune activity during fungus-associated respiratory disease.
Type 2 inflammation provides a framework for interpreting several measurable outcomes in the system, including immunoglobulin E production, eosinophil accumulation, mucus secretion, and heightened airway responsiveness. Focusing on this coordinated response helps distinguish pathways associated with fungus-driven allergic airway disease and supports evaluation of treatments designed to modify particular inflammatory mechanisms.
Because the initiating stimulus is Aspergillus fumigatus, investigators can examine inflammatory pathways in the context of fungal antigen exposure rather than treating allergic asthma as a single uniform process. Comparing the resulting immune and airway responses can clarify which mechanisms are associated with fungus-related disease, providing a basis for investigating targeted therapies and disease-specific biological interactions.
A common design begins with sensitization and is followed by inhalation or airway exposure to Aspergillus fumigatus spores or extracts. The exposure phase then permits assessment of the induced airway response. This sequence links prior immune conditioning with subsequent fungal challenge and provides a structured way to study how exposure produces allergic respiratory features.
Key outcomes include immunoglobulin E production, eosinophil recruitment, mucus secretion, and airway hyperresponsiveness. Together, these measurements capture immune activation, cellular infiltration, airway secretory changes, and altered respiratory reactivity. Examining the outcomes as a group helps determine whether a treatment changes the broader allergic airway response rather than only one individual marker.
The system is useful when researchers need to study allergic airway disease associated with environmental fungal exposure. It supports investigation of fungal antigen interactions with airway tissues and adaptive immunity, while also providing a context for evaluating potential asthma treatments. Its outcomes can help connect biological mechanisms with treatment effects in fungus-associated respiratory disease.